$NRSN

NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics is a clinical-stage biotechnology company headquartered in Herzliya, Israel. It discovers and develops treatments for people living with neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. Its development strategy combines drugs to target multiple disease-related pathways. NeuroSense’s lead therapeutic candidate, PrimeC, is an extended-release oral formulation combining ciprofloxacin and celecoxib. It is designed to treat ALS by regulating microRNA synthesis, influencing iron accumulation and reducing neuroinflammation. PrimeC has orphan drug designation for ALS from the U.S. Food and Drug Administration and the European Medicines Agency. NeuroSense also conducts research and development for Alzheimer’s and Parkinson’s diseases using a similar combination-product strategy.

No enriched coverage for $NRSN in the last 7 days.

No SEC Form 4 filings for $NRSN in the last 30 days.

See all $NRSN insider activity →
Med

NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data

NeuroSense Therapeutics (NRSN) plans to include new neurofilament light chain (NfL) data in its New Drug Submission (NDS) for PrimeC, its ALS treatment, to Health Canada. The filing, now targeted for March 2027, aims to strengthen the application with additional biomarker evidence. If approved, PrimeC could address approximately 4,000 Canadians living with ALS. The company is also advancing discussions with potential commercialization partners for Canada.

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

NeuroSense Therapeutics (NASDAQ: NRSN) will present clinical and biomarker data from its PARADIGM Phase 2b program at the 2026 NEALS Annual Meeting. The findings will inform the development strategy for its planned Phase 3 study (PARAGON) of PrimeC, a treatment for ALS. The company has received FDA clearance to initiate the PARAGON trial, which is designed to be more rigorous and efficient based on the PARADIGM results.

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

NeuroSense Therapeutics (NRSN) filed a U.S. patent application for PrimeC to treat traumatic brain injury (TBI) and related conditions. The patent, if granted, could extend to 2047. TBI affects millions annually with no approved disease-modifying therapies. NeuroSense aims to expand PrimeC's use beyond ALS, potentially increasing its commercial value. The company is evaluating research partnerships and non-dilutive funding opportunities.

NRSN sentiment & insider activity

Recent NRSN coverage spans regulation, technology and corporate actions.

What's driving NRSN

  • The inclusion of additional biomarker data strengthens the regulatory filing, potentially improving approval odds.

    prnewswire.com · Nov 2, 2026

  • Positive regulatory approval for a pivotal trial is likely to lift sentiment and drive buying pressure.

    prnewswire.com · Oct 29, 2026

  • The patent filing adds intellectual‑property protection for a new indication, which could broaden PrimeC's market potential and support future collaborations.

    prnewswire.com · Oct 19, 2026

  • Shares may face volatility around the hearing outcome; compliance success could support price, while a negative decision may pressure the stock.

    prnewswire.com · Oct 13, 2026

  • Unexpected upside despite compliance notice, possibly due to short covering.

    benzinga.com · Oct 5, 2026

AlphAI scores every news story that mentions NRSN with an AI model for sentiment and relevance, and aggregates insider trades from NeuroSense Therapeutics Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NRSN

Score
$NRSNMedAI 8/10Clinical / regulatory

NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data

NeuroSense Therapeutics (NRSN) plans to include new neurofilament light chain (NfL) data in its New Drug Submission (NDS) for PrimeC, its ALS treatment, to Health Canada. The filing, now targeted for March 2027, aims to strengthen the application with additional biomarker evidence. If approved, PrimeC could address approximately 4,000 Canadians living with ALS. The company is also advancing discussions with potential commercialization partners for Canada.

$NRSNHighAI 9/10

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

NeuroSense Therapeutics (NASDAQ: NRSN) will present clinical and biomarker data from its PARADIGM Phase 2b program at the 2026 NEALS Annual Meeting. The findings will inform the development strategy for its planned Phase 3 study (PARAGON) of PrimeC, a treatment for ALS. The company has received FDA clearance to initiate the PARAGON trial, which is designed to be more rigorous and efficient based on the PARADIGM results.

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

NeuroSense Therapeutics (NRSN) filed a U.S. patent application for PrimeC to treat traumatic brain injury (TBI) and related conditions. The patent, if granted, could extend to 2047. TBI affects millions annually with no approved disease-modifying therapies. NeuroSense aims to expand PrimeC's use beyond ALS, potentially increasing its commercial value. The company is evaluating research partnerships and non-dilutive funding opportunities.

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

NeuroSense Therapeutics (NRSN) has scheduled a Nasdaq hearing for November 10, 2026, to appeal a delisting determination. The company has regained compliance with the minimum bid price requirement but still needs to meet the market value or equity standard. NeuroSense is targeting a New Drug Submission to Health Canada for PrimeC in December 2026 and expects a decision on non-dilutive funding for its Phase 3 trial in Q1 2027.

NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense (NRSN) has regained compliance with Nasdaq's minimum bid price requirement but failed to meet the $35M market value requirement. The company plans to appeal and request additional time to comply. It also announced progress in its ALS treatment, PrimeC, with a Phase 3 trial planned.

$NRSNMedEarnings

NeuroSense Therapeutics Ltd. (NRSN): Financial results for H1 2026

NeuroSense Therapeutics Ltd. (NRSN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 NeuroSense Provides Business Update and Progress for the First Half of 2026 CAMBRIDGE, Mass., September 25, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company focused on developing disease-

$NRSNMedAI 8/10

NeuroSense Unveils Accelerated, Capital-Efficient PrimeC Development Strategy In ALS

NeuroSense Therapeutics (NRSN) announced a redesigned development strategy for PrimeC in ALS, aiming to accelerate regulatory approval and reduce costs. The strategy includes AI-enabled formulation analysis, a comparative study against edaravone, and an optimized Phase 3 trial design. The company has received FDA clearance and is targeting a Canadian regulatory submission by December 2026. PrimeC is an investigational oral therapy combining ciprofloxacin and celecoxib.

NeuroSense Issues CEO Letter to Shareholders

NeuroSense Therapeutics (NASDAQ: NRSN) said the FDA cleared it to start the Phase 3 PARAGON study of PrimeC in ALS, targeting about 300 participants, mainly in the U.S. The company is seeking financing to fund initiation, expects to submit an NDS in Canada in Dec 2026, and plans a possible 1:4 to 1:40 reverse split to address Nasdaq bid-price issues.

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NeuroSense Therapeutics (NASDAQ: NRSN) says it has completed the Pre-NDS process with Health Canada for its ALS drug PrimeC and is targeting an NDS filing in early December 2026. Health Canada aligned on submission content and structure and raised no concerns. The NDS would be supported by Phase 2b PARADIGM results, including HR 0.35 (p=0.0037) median survival benefit.

Related tickers